直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
    • AI + Finnegan
    • Appeals, Issues, and Legal Strategy
    • Diligence, Licensing, and Opinions
    • Global IP Enforcement, Litigation, and Trials
    • Patent Office Invalidation Proceedings
    • Prosecution and Portfolio Management
    • Trademark and Brand Management
    • AI, Electronics, and Information Technology
    • Chemicals, Industrials, and Materials
    • Communications
    • Consumer Goods and Services
    • Energy
    • Hospitality, Gaming, and Leisure
    • Life Sciences
    • Transportation and Logistics
  • Experience

Patent Oppositions and Appeals

About

Timing your opposition strategies

The opposition procedure offers third parties an opportunity to attack a European or German patent for a limited period after grant. This option is usually a much more appealing alternative to attacking it through the local procedures on a country-by-country basis after national ratification which can be more time consuming and costly, and the results may vary in different jurisdictions.

Finnegan’s European patent attorneys are experienced in all aspects of complex and high-value oppositions. We regularly defend clients’ patents, including against multiple opponents, and represent them in appeals against adverse decisions.

Finnegan’s extensive patent litigation experience combined with our knowledge of U.S. Patent and Trademark Office (USPTO) post-grant procedures also provides us with an educated perspective on how best to coordinate oppositions within a global context. Drawing on our experience in multi-jurisdictional coordination, we are not only able to maximize efficiencies, but we are also able to intelligently use the optimal combination of procedures and approaches to obtain the best results for each individual client.

Contacts

Dr. Antje Brambrink
Partner
Munich
+49 89 83931 1239
Email
Luigi Distefano
Partner
London
+44 (0)20 7864 2800
Email
Dr. Dr. Jochen Herr, LL.M.
Partner
Munich
+49 89 83931 1240
Email
Dr. Moritz Meckel
Partner
Munich
+49 89 83931 1235
Email
Yelena Morozova
Partner
London
+44 (0)20 7864 2819
Email
Maeve O'Flynn
Partner
London
+44 (0)20 7864 2856
Email
Dr. Antje Brambrink
Partner
Munich
+49 89 83931 1239
Email
Luigi Distefano
Partner
London
+44 (0)20 7864 2800
Email
Dr. Dr. Jochen Herr, LL.M.
Partner
Munich
+49 89 83931 1240
Email
Dr. Moritz Meckel
Partner
Munich
+49 89 83931 1235
Email
Yelena Morozova
Partner
London
+44 (0)20 7864 2819
Email
Maeve O'Flynn
Partner
London
+44 (0)20 7864 2856
Email

Everyone in this practice

Experience

Innovacell AG v. University of Pittsburgh*
Represented Innovacell in opposition related to muscle derived cells.

T 0527/17, EPO

Innovacell Biotechnologie AG v. University of Pittsburgh*
Represented Innovacell in opposition related to the use of myoblasts for treating the urinary sphincter muscle.

T 1031/16, EPO

Innovacell Biotechnologie AG v. University of Pittsburgh*
Represented Innovacell in opposition related to the use of myoblasts for treating stress urinary incontinence.

T 1050/12, EPO

Finnegan client BTG prevails in EPO opposition proceedings in the field of vein sclerotherapy
Finnegan represented BTG in defending its granted European patent in an appeal by Kreussler against the decision of the EPO to reject its opposition. The patent relates to BTG’s Varithena sclerotherapy foam product for treatment of varicose veins that has recently received regulatory approval in the U.S. During the opposition, we argued that the experimental evidence produced by Kreussler was deliberately misleading. We presented our own evidence showing why the experiments performed by Kreussler failed and how merely following the explicit teaching of the patent would avoid such failure. At appeal, Kreussler was limited to a single prior art document and only a subset of the granted claims was considered to be challenged. At the appeal hearing in surprisingly quick fashion, the EPO denied Kreussler’s grounds of appeal and maintained the patent in its granted form.

Appeal No. T1996/12-3.3.05, EPO

Defended patents of a provider of cinema technology in opposition proceedings before the European Patent Office*
Defended three patents of a world-leading provider of cinema technology in opposition proceedings before the European Patent Office, including two appeals. Enforced the same three patents against a competitor and its German distributor in infringement lawsuits and related appeals.

EPO

Represented a medical devices company before German Civil Courts and the European Patent Office (EPO)*
Advised and represented a medical devices company as the plaintiff in infringement proceedings and together with a patent attorney in the defense in opposition proceedings before the European Patent Office (EPO).

German Civil Patent Courts
EPO

More

Insights

Federal Circuit IP Blog

Federal Circuit Reverses Eligibility of Software Claims Where Technical Improvements Were Not Reflected in Claims

April 15, 2026

Articles

Different from U.S. Concepts of POSITA/PHOSITA, Proving “Common General Knowledge” Under German and the EPC Law: Why Proving Common General Knowledge Matters—and Why It’s Harder Than It Looks

December 1, 2025

Federal Circuit IP Blog

Federal Circuit Affirms Broad Functional Language Render Brita’s Patent Invalid Under §112(a)

October 29, 2025

Articles

Pre-Grant Description Amendments in Europe—No Enlarged Board of Appeal Referral

January 13, 2025

European IP Blog

When Is a Party Not a Party?

7 January 2025

European IP Blog

Opposition Proceedings Before the EPO – an Overview

20 February 2024

More

News

Award/Ranking

Finnegan Named Law Firm of the Year for Patent Law in the 2026 Best Law Firms Rankings

November 6, 2025

Award/Ranking

Finnegan Remains a Top Tier Firm in the 2025 Managing Intellectual Property IP Stars Rankings

May 30, 2025

Award/Ranking

Finnegan’s Munich Office Ranks in The Legal 500 Deutschland for Third Consecutive Year

February 13, 2025

Award/Ranking

Seven Finnegan Attorneys Recognized in the 2025 IAM Global Leaders Guide

October 23, 2024

Award/Ranking

Finnegan Ranked Top Tier in The Legal 500 2024 Rankings

June 13, 2024

Award/Ranking

46 Finnegan Attorneys Ranked in 2024 IAM Patent 1000

June 6, 2024

More

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP